Intravenous chimeric anti-CD20 monoclonal antibody that targets CD20 on B cells, inducing antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity, leading to B-cell depletion.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on B cells and induces antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity, leading to depletion of CD20-positive B cells.
YES
DIRECT
Rituximab binds CD20 on B cells and triggers Fc-mediated ADCC/ADCP and complement-dependent cytotoxicity (CDC), leading to lysis and depletion of CD20+ cells.
Therapeutic EBV-directed immunotherapy (intradermal/subcutaneous) designed to elicit or boost EBV-specific cytotoxic T-cell responses against EBV antigens on infected lymphocytes.
Intradermal/subcutaneous administration of EBV antigenic peptides is taken up by antigen‑presenting cells and presented on MHC I/II, priming and boosting EBV‑specific CD8+ and CD4+ T‑cell responses that recognize EBV antigens on infected lymphocytes, leading to targeted cytotoxic killing of EBV‑infected cells.
YES
INDIRECT
Peptide vaccine primes EBNA1-specific CD8+/CD4+ T cells; CTLs recognize EBNA1-derived peptides on MHC of infected cells and kill via perforin/granzyme (and Fas–FasL) apoptosis.
Therapeutic EBV-directed immunotherapy (intradermal/subcutaneous) designed to elicit or boost EBV-specific cytotoxic T-cell responses against EBV antigens on infected lymphocytes.
Intradermal/subcutaneous administration of EBV antigenic peptides is taken up by antigen‑presenting cells and presented on MHC I/II, priming and boosting EBV‑specific CD8+ and CD4+ T‑cell responses that recognize EBV antigens on infected lymphocytes, leading to targeted cytotoxic killing of EBV‑infected cells.
YES
INDIRECT
Peptide immunization primes EBV-specific CD8+ T cells that recognize LMP1-derived peptides on MHC I of infected cells and kill them via perforin/granzyme (and Fas–FasL) pathways.
Therapeutic EBV-directed immunotherapy (intradermal/subcutaneous) designed to elicit or boost EBV-specific cytotoxic T-cell responses against EBV antigens on infected lymphocytes.
Intradermal/subcutaneous administration of EBV antigenic peptides is taken up by antigen‑presenting cells and presented on MHC I/II, priming and boosting EBV‑specific CD8+ and CD4+ T‑cell responses that recognize EBV antigens on infected lymphocytes, leading to targeted cytotoxic killing of EBV‑infected cells.
YES
INDIRECT
Vaccination primes EBV-specific CD8+ T cells that recognize LMP2-derived peptides on MHC I of infected cells and kill them via perforin/granzyme-mediated cytotoxicity.
Therapeutic EBV-directed immunotherapy (intradermal/subcutaneous) designed to elicit or boost EBV-specific cytotoxic T-cell responses against EBV antigens on infected lymphocytes.
Intradermal/subcutaneous administration of EBV antigenic peptides is taken up by antigen‑presenting cells and presented on MHC I/II, priming and boosting EBV‑specific CD8+ and CD4+ T‑cell responses that recognize EBV antigens on infected lymphocytes, leading to targeted cytotoxic killing of EBV‑infected cells.
YES
INDIRECT
Peptide vaccination primes/expands EBV-specific CTLs that recognize BZLF1-derived peptides on MHC I of infected lymphocytes and kill them via perforin/granzyme-mediated cytotoxicity.